Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020.
Magrolimab是吉利德科學公司（納斯達克：GILD）於2020年3月以49億美元收購Forty Seven Inc的核心。
Magrolimab is a monoclonal antibody targeting CD47 for treating various types of blood cancers. But the drug has repeatedly hit speed breakers.
Magrolimab是一種單克隆抗體，用於治療各種類型的血液癌症。但該藥物已經多次遇到了瓶頸。
Over the weekend, at the European Hematology Association meeting, Gilead unveiled additional data from the halted trials.
在上週末的歐洲血液學協會會議上，吉利德公佈了中止試驗的額外數據。
In Phase 3 trial ENHANCE, 539 patients with high-risk myelodysplastic syndromes received either magrolimab and azacitidine (standard treatment) or placebo plus standard treatment.
在第三階段試驗ENHANCE中，539名患有高風險骨髓增生異常綜合症的患者分別接受了Magrolimab和阿扎胞苷（標準治療）或安慰劑加標準治療。
More magrolimab + azacitidine arm patients discontinued treatment due to adverse events versus the placebo + azacitidine arm.
與安慰劑+阿扎胞苷組相比，更多的Magrolimab +阿扎胞苷組患者因不良事件而停止治療。
The number of patients who proceeded to transplant was higher in the placebo + azacitidine arm (35.4%) compared to the magrolimab + azacitidine arm (20.9%).
在安慰劑+阿扎胞苷組中，轉化爲移植的患者比Magrolimab +阿扎胞苷組高（35.4％對20.9％） 。
The study did not meet the primary endpoints of overall survival (median, 15.9 vs. 18.6 months or complete remission rates (CRR) (21.3% vs. 23.6%).
該研究未達到總生存期（中位數，15.9 vs. 18.6個月）或完全緩解率（CRR）（21.3％vs. 23.6％）的主要終點。
The study showed more severe TEAEs overall, including a higher rate of Grade ≥3 TEAEs.
該研究顯示了更嚴重的TEAEs，包括更高比率的≥3級TEAEs。
42.6% of patients in the magrolimab arm experienced anemia compared to 21.2% in the placebo arm.
Magrolimab組中有42.6％的患者經歷了貧血，而安慰劑組中爲21.2％。
And 24% of patients in the magrolimab arm discontinued the study compared to 12.1 in the placebo group.
Magrolimab組中24％的患者中止了研究，而安慰劑組中則有12.1％。
A second phase 3 study, ENHANCE-3, enrolled 378 untreated acute myeloid leukemia patients who weren't eligible for intensive chemotherapy.
第二個第三階段研究ENHANCE-3招募了378名未接受強化化療的急性髓系白血病患者。
In this study, patients received either magrolimab or a placebo on top of azacitidine and Venclexta.
在這項研究中，患者接受了Magrolimab或安慰劑，同時使用阿扎胞苷和Venclexta。
With a median follow-up of 5.4 months, the median overall survival in the magrolimab and placebo arms was 11.7 vs. 10.4 months, respectively.
在中位隨訪5.4個月後，Magrolimab和安慰劑組的中位總生存期分別爲11.7和10.4個月。
There were more deaths in the magrolimab arm (n=68, 36.0%) than in the placebo arm (n=58, 30.7%).
在Magrolimab組中，死亡人數（n=68，36.0％）比安慰劑組（n=58，30.7％）更多。
In the magrolimab vs. placebo arm, the complete remission (CR) rate within six treatment cycles was 39.7% vs. 42.9%, the median time to CR was 1.08 vs. 1.87 months, and the duration of CR was 7.8 vs. 8.1 months.
在Magrolimab與安慰劑組中，在六個治療週期內的完全緩解（CR）率分別爲39.7％對42.9％，CR的中位時間分別爲1.08對1.87個月，CR的持續時間分別爲7.8對8.1個月。
A higher incidence of Grade≥ 3 anemia (39.7% vs. 25.0%) and Grade ≥3 infusion-related reactions (3.7% vs. 1.6%) was observed in the magrolimab and placebo arm.
在Magrolimab和安慰劑組中觀察到≥3級貧血（39.7％對25.0％）和≥3級輸注相關反應（3.7％對1.6％）的發生率更高。
Price Action: GILD shares are down 0.95% at $64.44 at last check Monday.
股價走勢：截至最後一次交易時，GILD股票下跌0.95％，至64.44美元。
譯文內容由第三人軟體翻譯。